Ghrelin-receptor activation
Ipamorelin activates the growth-hormone secretagogue receptor, a signaling target associated with ghrelin biology.
P—11 • Investigational research profile
Ipamorelin
A concise educational overview of a synthetic growth-hormone secretagogue studied for ghrelin-receptor signaling and endogenous growth-hormone release.
Name
Ipamorelin
Also encountered as ipamorelin acetate
- Scientific classification
- Synthetic pentapeptide growth-hormone secretagogue and ghrelin-receptor agonist
- Library family
- Hormonal
- Research status
- Investigational; supported by preclinical pharmacology and limited human clinical research
- Regulatory status
- Not FDA approved; ipamorelin acetate is identified by FDA as a Category 2 compounding substance that may present significant safety risks
Compound overview
A synthetic peptide that activates ghrelin-related growth-hormone signaling.
Ipamorelin is a synthetic peptide designed to activate the growth-hormone secretagogue receptor, also called GHS-R1a, and stimulate the body's own release of growth hormone.
Unlike CJC-1295, which acts through the growth-hormone-releasing hormone receptor, ipamorelin primarily targets the ghrelin receptor. Its clinical benefits have not been established.
Mechanism under study
Ghrelin-receptor signaling and endogenous growth-hormone release
Ipamorelin acts upstream of growth hormone through GHS-R1a signaling. A functioning pituitary is required for this type of secretagogue to produce its intended hormonal effect.
Pituitary hormone release
Receptor activation stimulates growth-hormone release from pituitary somatotroph cells.
Downstream signaling
Growth hormone can influence production of insulin-like growth factor 1 and other downstream endocrine pathways.
Preclinical studies reported less ACTH and cortisol stimulation than with certain older secretagogues. This should not be interpreted as proof of broad selectivity or safety in humans.
Current research areas
Questions under investigation
- Growth-hormone secretagogue pharmacology
- GHS-R1a receptor selectivity
- Growth hormone and IGF-1 signaling
- Gastrointestinal motility and postoperative ileus
- Endocrine, metabolic, and long-term safety
Evidence summary
Growth-hormone signaling research findings
- Growth-hormone release: Preclinical and early research demonstrates a measurable secretagogue effect.
- Receptor selectivity: Preclinical studies suggest greater hormonal selectivity than certain earlier growth-hormone-releasing peptides.
- Gastrointestinal motility: A Phase 2 trial tested intravenous ipamorelin after bowel resection but did not demonstrate significant improvement in its primary or secondary efficacy outcomes.
- Broader research applications: Controlled studies are needed to determine whether the observed hormonal effects translate into meaningful metabolic, recovery, or performance outcomes.
- Long-term research: Continued study can help clarify durability, clinical relevance, and long-term safety.
The observed growth-hormone response supports continued study; clinical, metabolic, recovery, and performance relevance remains unestablished.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, treatment guidance, dosing information, or instructions for ipamorelin use. The FDA has raised concerns involving immunogenicity, peptide aggregation, impurities, unnatural amino-acid characterization, serious adverse events reported in an intravenous clinical trial, and insufficient safety information for other injectable routes.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.